Stockreport

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024 [Yahoo! Finance]

Cardiol Therapeutics Inc. - Class A Common Shares  (CRDL) 
PDF ARCHER trial rationale and design also accepted for publication in the journal ESC Heart Failure ARCHER trial has now exceeded 85% of target patient enrollment MAvE [Read more]